Clinical Trials Logo

Carcinoma clinical trials

View clinical trials related to Carcinoma.

Filter by:

NCT ID: NCT00993616 Completed - Clinical trials for Fallopian Tube Cancer

Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin

Start date: December 2009
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well giving belinostat together with carboplatin works in treating patients with recurrent or persistent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer that did not respond to carboplatin or cisplatin. Belinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving belinostat together with carboplatin may kill more tumor cells.

NCT ID: NCT00992121 Completed - Clinical trials for Carcinoma, Renal Cell

An Open-Label Pharmacodynamic Study of Bevacivumab and Pazopanib in Renal Cell Carcinoma

Start date: November 18, 2009
Phase: Phase 1
Study type: Interventional

This study will determine whether blood tests, tumour imaging and tumour tissue analysis can reveal effects of drugs that block blood vessel growth (angiogenesis) in patients with renal cancer.

NCT ID: NCT00989651 Completed - Clinical trials for Primary Peritoneal Carcinoma

Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Start date: October 28, 2009
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of veliparib when given together with carboplatin, paclitaxel, and bevacizumab in treating patients with newly diagnosed stage II-IV ovarian epithelial, fallopian tube, or primary peritoneal cancer. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cells to repair themselves from damage and survive. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Bevacizumab, a type of drug called a monoclonal antibody, blocks tumor growth by targeting certain cells and preventing the growth of new blood vessels that tumors need to grow. Giving veliparib together with carboplatin, paclitaxel, and bevacizumab may kill more tumor cells.

NCT ID: NCT00988741 Completed - Clinical trials for Unresectable Hepatocellular Carcinoma

Trial of ARQ 197 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Who Have Failed One Prior Systemic Therapy

Start date: September 2009
Phase: Phase 2
Study type: Interventional

This is a global randomized, placebo-controlled, double-blinded Phase 2 study designed to compare treatment of ARQ 197 versus placebo in patients with unresectable HCC who had radiographic disease progression after systemic first line therapy or were unable to tolerate the therapy.

NCT ID: NCT00988455 Completed - Clinical trials for Basal Cell Carcinoma

Evaluation of Efficacy of Photodynamic Therapy in Basal Cell Carcinoma With 6 Months Follow-up

Start date: January 2008
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy of photodynamic therapy (PDT)in treatment of Basal cell carcinoma (BCC) and recurrence rate after 6 months.

NCT ID: NCT00988195 Completed - Clinical trials for Hepatocellular Carcinoma

Study of Pegylated Human Recombinant Arginase for Liver Cancer

Start date: May 2008
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine whether recombinant human arginase (PEG-BCT-100) is safe and effective in the treatment of advanced hepatocellular carcinoma (HCC).

NCT ID: NCT00987935 Completed - Clinical trials for Carcinoma, Hepatocellular

A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients

Start date: October 2009
Phase: Phase 2
Study type: Interventional

This study is to evaluate the safety, appropriate dose, and efficacy of BIBF 1120 in liver cancer patients

NCT ID: NCT00985829 Completed - Clinical trials for Basal Cell Carcinoma

Evaluation of Efficacy of Photodynamic Therapy in Basal Cell Carcinoma

Start date: January 2008
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the efficacy of pdt in treatment of bcc and factors that affect response rate.

NCT ID: NCT00979992 Completed - Clinical trials for Recurrent Ovarian Carcinoma

Sunitinib Malate in Treating Patients With Persistent or Recurrent Clear Cell Ovarian Cancer

Start date: April 19, 2010
Phase: Phase 2
Study type: Interventional

This phase II trial studies the side effects of sunitinib malate and how well it works in treating patients with ovarian cancer that is persistent or has come back. Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

NCT ID: NCT00976170 Completed - Clinical trials for Hepatocellular Carcinoma

Study of GC33 and Sorafenib in Combination in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)

Start date: September 2009
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the safety and best dose of GC33 and Sorafenib in combination in patients with advanced or metastatic liver cancer.